One-Size-Fits-All for AML? Not Anymore

By Ilana Yurkiewicz, MD Once upon a time, there was “7+3.” Developed in the 1970s, this easy-to-remember induction chemotherapy regimen for acute myeloid leukemia (AML) went largely unchanged for decades. But in the past few years, we have seen multiple new drug...

Mission (Im)Possible

By Binod Dhakal, MD, MS The year 1982 heralds the discovery of the first mutated genes to be identified in cancer, RAS. The three RAS genes — KRAS, NRAS, and HRAS — still constitute the most frequently mutated oncogene family in human cancers. However, despite more...